Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Lipidor Signs Agreement With CRO for Implementation of Phase III Clinical Study of Drug Candidate AKP-02 Against Psoriasis

prnasiaJuly 08, 2020

Tag: Lipidor , CRO , AKP-02 Against Psoriasis

PharmaSources Customer Service